Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.NEWTON, Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY.
馬薩諸塞州牛頓，2024年11月25日，Karyopharm Therapeutics公司（納斯達克：KPTI）是一家商業階段的藥品公司，開創了新型癌症療法，今天宣佈公司的高級管理團隊將參加派傑投資第36屆年度醫療保健大會，在紐約時間12月3日上午11:30進行爐邊聊天。紐約，紐約州。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
可以在公司網站的投資者部分的「事件與演示文稿」下訪問爐邊聊天的現場網絡廣播，並在活動結束後提供回放。
About Karyopharm Therapeutics
關於Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics公司（納斯達克：KPTI）是一家商業階段的藥品公司，致力於開創新型癌症療法，其動力來自對癌症患者非凡的力量和勇氣的信仰。自成立以來，Karyopharm一直是口服化合物領域的行業領導者，涉及核蛋白輸出失調，這是癌症發生的基本機制。Karyopharm的首個口服輸出蛋白1（XPO1）抑制劑和首創藥物XPOVIO（西立諾司）在美國獲批，由公司在三個腫瘤治療適應症中銷售。它還在越來越多的非美國領土和國家，包括歐洲、英國（作爲NEXPOVIO）和中國，獲得了各種適應症的監管批准。Karyopharm專注於多種高度不滿足需求的癌症適應症，包括多發性骨髓瘤、子宮內膜癌、骨髓纖維化和瀰漫大B細胞淋巴瘤（DLBCL）。有關我們的人員、科學和管線的更多信息，請訪問 ，並在領英和X上關注我們@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的註冊商標。本新聞稿中提到的任何其他商標均爲其各自所有者的財產。
SOURCE Karyopharm Therapeutics Inc.
來源：karyopharm therapeutics公司
譯文內容由第三人軟體翻譯。
